Fer-In-Sol

DRUG3 trials

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Rockwell Medical Technologies, Inc.

Conditions

AnemiaIron DeficiencyIron-Refractory Iron-Deficiency AnemiaIron-refractory, Iron-deficiency Anemia (IRIDA)

Phase 1

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

CompletedNCT02767128

Rockwell Medical Technologies, Inc.Iron-refractory, Iron-deficiency Anemia (IRIDA)

Start: 2016-04-30End: 2016-04-30Updated: 2019-02-01

Phase 2

Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

TerminatedNCT02905981

Rockwell Medical Technologies, Inc.Iron-Refractory Iron-Deficiency Anemia

Start: 2017-01-17End: 2018-03-15Updated: 2020-09-22

Phase 4

Prevention of Iron Deficiency in Breastfed Infants

CompletedNCT01444261

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Anemia, Iron Deficiency

Start: 2010-12-31End: 2014-04-30Updated: 2017-03-31